| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 97.40 |
| The Vanguard Group, Inc. | 7.65 |
| Capital Research & Management Co. (World Investors) | 5.05 |
| Vanguard Health Care Fund | 2.40 |
| American Funds Growth Fund of America | 1.94 |
| George Damis Yancopoulos, MD, PhD | 1.16 |
| Norges Bank (13F) | 0.90 |
| Sands Capital Management LLC | 0.80 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 6’200 | 7’400 | 8’100 | 9’123 | 10’368 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.95 | 0.91 | 0.97 | 0.93 | 1.55 |
Bilanz (in Mio. EUR) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 4’335 | 6’448 | 7’689 | 9’779 | 14’015 |
| Summe Anlagevermögen | 6’848 | 9’466 | 11’804 | 13’721 | 21’469 |
| Summe Aktiva | 8’812 | 11’735 | 14’805 | 17’163 | 25’435 |
Bilanz (in Mio. EUR) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 703 | 709 | 714 | 2’696 | 2’700 |
| Summe Fremdkapital | 2’668 | 2’977 | 3’716 | 6’138 | 6’666 |
| Summe Eigenkapital | 6’144 | 8’757 | 11’090 | 11’025 | 18’769 |
| Summe Passiva | 8’812 | 11’735 | 14’805 | 17’163 | 25’435 |
Adresse
| 777 Old Saw Mill River Road, 10591-6707 Tarrytown | |
| Telefon | +1 (914) 847-7000 |
| URL | http://www.regeneron.com |
Management
|
Alan Shuldiner
Vice President-Translational Genetics |
|
Andrew J. Murphy
Executive Vice President-Research |
|
Arthur Frederick Ryan
Independent Director |
|
Beth F. Holly
Chief Compliance Officer & Senior Vice President |
|
Bob McCowan
Chief Information Officer & Senior VP-IT |
|
Bonnie L. Bassler
Independent Director |
|
Christine A. Poon
Independent Director |
|
Christopher Robert Fenimore
Senior VP, Head-Accounting & Controller |
|
Daniel P. van Plew
EVP, GM-Industrial Operations & Product Supply |
|
David Weinreich
Senior Vice President-Global Clinical Development |
|
George Damis Yancopoulos
Co-President, Director & Chief Scientific Officer |
|
George L. Sing
Independent Director |
|
Gerald Underwood
Senior Vice President-Technical Operations |
|
Huda Y. Zoghbi
Independent Director |
|
Joseph J. LaRosa
Secretary, Executive VP & General Counsel |
|
Joseph L. Goldstein
Independent Director |
|
Kerry K. Reinertsen
Senior Vice President-Strategic Alliances |
|
Leonard S. Schleifer
Co-President, Chief Executive Officer & Director |
|
Marc Tessier-Lavigne
Independent Director |
|
Marion McCourt
Executive Vice President-Commercial |
|
Mark Hudson
Head-Investor Relations |
|
Maya Bermingham
Senior VP, Public Policy & Government Affairs |
|
Michael S. Brown
Independent Director |
|
N. Anthony Coles
Independent Director |
|
Ned Braunstein
SVP-Regulatory Affairs & Global Patient Safety |
|
Neil Stahl
Executive VP-Research & Development |
|
Nouhad Husseini
Senior VP-Business Development |
|
P. Roy Vagelos
Chairman |
|
Patrice Gilooly
Senior VP-Quality Assurance & Operations |
|
Robert E. Landry
Chief Financial Officer & Executive VP-Finance |
|
Sally A. Paull
Senior Vice President-Human Resources |